The U.S. Food and Drug Administration has approved bosulif for the treatment of chronic myelogenous leukemia (CML), a condition primarily afflicting older individuals.
CML "causes a person's bone marrow to produce an enzyme that triggers development of abnormal white blood cells"; bosulif aids in blocking the effects of this enzyme.
To read more about these findings, click here.
No comments:
Post a Comment